Western pharmaceutical companies need to tap into “mind-bogglingly impressive innovation” in China despite “anti-Chinese sentiment” in US life sciences, according to the chief executive of Genmab, one of Europe’s leading biotech companies.Jan van de Winkel, head of the DKK132bn ($19bn) Danish biotech that recently announced its first acquisition by buying a US-Chinese drugmaker, said that pharma groups cannot ignore Chinese biotechs that “are growing very, very rapidly with the government there investing massive amounts of money”.
欧洲领先生物技术公司之一Genmab的首席执行官表示，尽管美国生命科学领域存在“反华情绪”，但西方制药公司需要对manbetx3.0 “令人印象深刻到难以置信程度的创新”加以利用。
您已阅读11%（617字），剩余89%（5128字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。